A systems-based explanation of lipid traffic, metabolic terrain, organ signals and what statins change
Executive summary
A rising LDL cholesterol result, falling HDL cholesterol and rising triglycerides often describe one connected failure of fuel handling. Fat cells release too much stored fat, the liver receives more fuel than it can safely process, the liver exports more triglyceride-rich particles, and the blood clears those particles too slowly. The resulting traffic changes the size, cholesterol content and lifetime of LDL and HDL particles. However, the same laboratory pattern can also arise from low thyroid function, inherited receptor defects, kidney protein loss, liver or bile-flow disease, menopause, alcohol, medication, rapid weight change or a diet that raises LDL in a susceptible person. Therefore, the pattern must be interpreted as biology, not as a label.
The central measurement error is to confuse cholesterol mass with particle number. LDL-C measures how much cholesterol is carried inside LDL particles. ApoB estimates how many potentially artery-entering particles are circulating because each VLDL, IDL, LDL and lipoprotein(a) particle carries one ApoB molecule. When triglycerides are high and insulin resistance is present, LDL particles often become smaller and carry less cholesterol. LDL-C can then look acceptable while ApoB remains high. Conversely, LDL-C can be high because each particle is cholesterol-rich even when the rise in particle number is smaller. The safest interpretation uses LDL-C, non-HDL-C, ApoB, triglycerides and the metabolic and organ context together.
Statins lower the liver’s internal cholesterol production. The liver responds by placing more LDL receptors on its surface, which removes more LDL, IDL and remnant particles from blood. Consequently, LDL-C, non-HDL-C and ApoB usually fall, triglycerides often fall modestly and HDL-C may rise slightly. This materially lowers atherosclerotic cardiovascular risk, particularly when cardiovascular disease is already present. However, a statin does not automatically reverse visceral fat, insulin resistance, fatty liver, excess alcohol exposure, low thyroid function, kidney disease, poor sleep, smoking or high blood pressure. It reduces dangerous particle traffic while the upstream terrain still requires direct assessment and correction.
The core principle is simple: treat particle exposure according to cardiovascular risk, while also finding and changing the biology that created the pattern.
1. Start with the right model
Cholesterol and triglycerides are essential fats. Cholesterol helps build cell membranes, steroid hormones, vitamin D and bile acids. Triglycerides are the body’s main transport and storage form of energy. Because fat does not dissolve in water, the body carries it through blood inside packages called lipoproteins. The package matters as much as the cargo.
The main ApoB-containing packages are chylomicrons from the intestine and VLDL from the liver, followed by their smaller descendants, IDL and LDL. Lipoprotein(a), written Lp(a), is an LDL-like particle with an additional protein attached. These particles can enter the artery wall if their number and exposure time are high enough. HDL is a different family of particles built mainly around ApoA-I. HDL participates in cholesterol transport and many repair functions, but HDL-C measures only the cholesterol inside HDL, not how well HDL works.
Therefore, “bad cholesterol” and “good cholesterol” are weak biological descriptions. LDL-C is cargo inside one particle class. HDL-C is cargo inside another. Triglycerides are fuel cargo. ApoB is a count of the major atherogenic vehicles. Non-HDL-C is the cholesterol carried in all ApoB-containing particles combined. The clinical question is not merely how much cholesterol is present. It is how many particles are circulating, what they carry, how long they remain in blood and why the liver, fat tissue, muscle, thyroid and kidneys created that traffic pattern.
2. Normal lipid traffic, step by step
First, after a meal, the intestine packages dietary triglyceride and cholesterol into chylomicrons. Each chylomicron carries one ApoB-48 molecule. These large particles deliver meal-derived fat to muscle for energy and to fat tissue for storage. An enzyme called lipoprotein lipase sits along small blood vessels and unloads triglyceride from the particle. What remains becomes a chylomicron remnant, which the liver normally removes.
Meanwhile, the liver packages internally produced triglyceride and cholesterol into VLDL. Each VLDL particle carries one ApoB-100 molecule. Lipoprotein lipase then removes triglyceride from VLDL. As the particle loses triglyceride, it becomes IDL and may later become LDL. LDL is therefore not simply eaten cholesterol entering the blood. Much of it is the final product of a transport chain that began with liver-made VLDL.
Next, LDL receptors on liver cells bind ApoB-containing particles and pull them out of circulation. A receptor can be reused many times. The number and activity of these receptors strongly influence LDL levels. PCSK9 is a protein that directs some LDL receptors for destruction. Higher PCSK9 activity leaves fewer receptors available, while lower PCSK9 activity allows more receptors to return to the liver surface.
At the same time, HDL particles collect cholesterol from tissues and exchange lipids with other particles. An exchange protein called CETP transfers triglyceride from VLDL into LDL and HDL while moving cholesterol in the opposite direction. A liver enzyme called hepatic lipase then remodels triglyceride-rich LDL and HDL. This system works well when fuel entry, liver production and particle clearance remain balanced.
3. The common metabolic sequence behind high triglycerides, low HDL and rising LDL
The first shift is insulin resistance
Insulin normally tells fat cells to stop releasing stored fat after food has arrived. In insulin resistance, fat cells respond poorly to that signal. Consequently, more free fatty acids escape from fat tissue into blood and travel to the liver, even when the body already has enough incoming energy. Visceral fat, which surrounds abdominal organs, is especially active in this process.
At the same time, repeated exposure to excess refined carbohydrate, sugar and total energy can push the liver to convert carbohydrate into fat. This process is called de novo lipogenesis, meaning new fat made inside the liver. Fructose is handled largely by the liver and can add to this pressure when intake is high. Therefore, the liver receives fat from two directions: released body fat and newly manufactured fat.
The second shift is liver triglyceride overload
The liver has three main choices for incoming fat. It can burn it, store it or export it. When supply repeatedly exceeds burning capacity, liver triglyceride accumulates and fatty liver can develop. To protect itself, the liver also exports more triglyceride in VLDL particles. In insulin-resistant states, ApoB-containing VLDL assembly is less effectively switched off, so both the number and triglyceride load of VLDL particles can rise.
This is why high triglycerides often connect with central weight gain, high fasting insulin, rising glucose, fatty liver, higher blood pressure and raised uric acid. They are different outputs of the same energy-handling strain. However, a normal ALT does not exclude fatty liver, and a normal fasting glucose does not exclude high insulin. The system may compensate for years before glucose crosses a diagnostic threshold.
The third shift is slower triglyceride clearance
Production is only half the problem. Triglyceride also rises when VLDL and chylomicrons are unloaded or cleared too slowly. Insulin resistance can reduce effective lipoprotein lipase action and increase ApoC-III, a protein that slows triglyceride removal and remnant uptake. Alcohol can sharply increase liver triglyceride production. Poorly controlled diabetes, low thyroid function, kidney disease, some medicines and genetic variants can further slow clearance. Therefore, fasting and post-meal triglycerides remain elevated for longer.
Once triglyceride-rich particles remain in circulation, they create more cholesterol-rich remnants. These remnants are smaller than new VLDL and can enter the artery wall. Triglyceride itself is mainly a marker of this traffic. The cholesterol inside remnant particles is the material retained within plaque. This is why non-HDL-C, ApoB and remnant cholesterol add information beyond triglycerides alone.
The fourth shift is HDL remodeling and faster HDL loss
As VLDL rises, CETP transfers more triglyceride into HDL. The HDL particle becomes triglyceride-rich and cholesterol-poor. Hepatic lipase then cuts triglyceride from this altered HDL, creating a smaller, less stable particle. ApoA-I can detach and be cleared more rapidly through the kidneys. Consequently, the measured HDL-C falls.
Therefore, low HDL-C in this setting is usually a signal of high triglyceride traffic, insulin resistance, smoking, inactivity or inflammation. It is not simply a shortage that should be corrected by forcing the number upward. Trials and genetic studies show that raising HDL-C alone does not reliably reduce cardiovascular events. Improving the terrain can raise HDL-C, but the important outcome is lower ApoB particle burden, lower remnant exposure and improved metabolic function, not a cosmetic HDL target.
The fifth shift is LDL remodeling
CETP also transfers triglyceride into LDL. Hepatic lipase then removes that triglyceride and leaves a smaller, denser LDL particle. Each small LDL particle carries less cholesterol than a larger LDL particle. Therefore, many small particles can circulate while LDL-C appears only mildly raised or even normal. ApoB reveals this hidden particle number because every LDL particle still carries one ApoB molecule.
Small LDL can remain in circulation and enter the artery wall, but size is not the main accounting system. The more fundamental exposure is the total number of ApoB particles and the length of time they circulate. Particle size can explain discordance; it should not replace ApoB, non-HDL-C or overall risk assessment.
The sixth shift is either rising LDL-C or hidden LDL particle excess
Some VLDL particles become LDL. If the liver produces more VLDL than its receptors can ultimately clear, LDL particle number rises. LDL-C may then rise as well. However, the exact laboratory appearance depends on how much cholesterol each LDL particle carries. One person may show high triglycerides, low HDL-C, near-normal LDL-C and high ApoB. Another may show high triglycerides, low HDL-C, high LDL-C and high ApoB. Both can reflect excess ApoB traffic, but the first is easier to miss.
4. Why LDL can rise for reasons beyond insulin resistance
LDL rises whenever production exceeds clearance. The cause can be more ApoB particle production, more cholesterol loaded into each particle, fewer functioning LDL receptors or a combination of all three. Therefore, the triglyceride and HDL context determines which mechanism is most likely.
Inherited disorders can reduce LDL receptor number or function, alter ApoB binding or increase PCSK9 activity. In familial hypercholesterolaemia, LDL is often high from early life, triglycerides may be normal and family members may have premature cardiovascular disease. Because exposure begins early, lifetime particle burden is high even when the person is lean and metabolically fit.
Low thyroid function reduces the liver’s ability to clear LDL and convert cholesterol into bile acids. Consequently, LDL-C and ApoB can rise, sometimes with higher triglycerides. The key context is TSH together with free T4, symptoms and repeat testing. Treating a true thyroid disorder can materially change the lipid pattern, whereas simply escalating lipid medication without checking thyroid function can leave an upstream cause untreated.
Diet can also alter receptor clearance and particle cholesterol. In susceptible people, high saturated fat intake can raise LDL-C and ApoB, particularly when it replaces unsaturated fat. Dietary cholesterol has a smaller average effect but can matter in hyper-responders. Conversely, soluble fibre and bile-acid loss through the gut can increase liver demand for cholesterol and support LDL clearance. The correct conclusion is not that one food affects everyone identically, but that the lipid response should be measured after a stable dietary period.
Very-low-carbohydrate diets commonly lower triglycerides and raise HDL-C, yet LDL-C and ApoB can rise substantially in some people, especially lean, active individuals with high fat turnover. This is not the classic high-triglyceride, low-HDL insulin-resistant pattern. It requires separate evaluation of ApoB, non-HDL-C, thyroid status, saturated-fat exposure, genetics, Lp(a), family history and existing plaque rather than assuming that low triglycerides cancel high ApoB exposure.
Kidney disease creates two different patterns. Chronic kidney disease often slows triglyceride-rich particle clearance and raises triglycerides. Nephrotic syndrome, in which large amounts of protein leak into urine, can sharply raise LDL and triglycerides as the liver increases protein and lipoprotein production and PCSK9 rises. Therefore, creatinine, eGFR, urine albumin-to-creatinine ratio, total urine protein and serum albumin belong in unexplained dyslipidaemia assessment.
Liver and bile-flow disease can also distort LDL measurement. Fatty liver commonly accompanies high triglycerides and ApoB overproduction. In contrast, cholestasis, which means impaired bile flow, can produce an abnormal particle called lipoprotein X that may be counted as LDL-C by some methods. High alkaline phosphatase, GGT and bilirubin make this possibility more relevant. This is a different problem from ordinary LDL excess and needs medical assessment.
Finally, menopause, excess glucocorticoid exposure, poorly controlled diabetes, heavy alcohol intake and several medicines can change lipid handling. Relevant medicines include some corticosteroids, retinoids, antipsychotics, HIV therapies, beta-blockers, thiazide diuretics, oestrogen formulations and immunosuppressants. A rising result should therefore trigger a timeline review: what changed in weight, diet, alcohol, sleep, illness, hormones, medication, supplements and laboratory conditions before the blood draw?
5. How to read the lipid biomarkers as one system
LDL-C, ApoB and non-HDL-C answer different questions
LDL-C measures cholesterol mass inside LDL. ApoB estimates the number of VLDL, IDL, LDL and Lp(a) particles. Non-HDL-C is total cholesterol minus HDL-C, so it captures cholesterol carried by all ApoB-containing particles. When triglycerides are high, diabetes is present or treatment has already lowered LDL-C, ApoB can show residual particle risk that LDL-C misses. The 2026 multisociety dyslipidaemia guideline specifically highlights ApoB in people with cardiovascular-kidney-metabolic disease, diabetes, high triglycerides or established cardiovascular disease.
Discordance is clinically important. High ApoB with lower LDL-C means many cholesterol-poor particles, a pattern common in insulin resistance. High LDL-C with a smaller ApoB rise means fewer but cholesterol-richer particles. The artery is exposed to particles, not laboratory cholesterol molecules in isolation. Therefore, when LDL-C and ApoB disagree, the particle count deserves particular attention.
Triglycerides and remnant cholesterol reveal fuel traffic
Triglycerides are highly responsive to recent food, alcohol, glucose control, weight change, exercise and fasting duration. A single mild elevation should be repeated under comparable conditions. Persistent elevation points toward excess liver output, slow clearance or both. Non-fasting triglycerides can be useful because people spend much of the day in a fed state, but very high results need prompt confirmation and assessment. At around 1,000 mg/dL, or 11.3 mmol/L, pancreatitis risk becomes a major clinical concern and treatment priorities change.
Remnant cholesterol is the cholesterol carried in triglyceride-rich remnants. It is sometimes estimated as total cholesterol minus LDL-C minus HDL-C, although calculated values become less reliable when triglycerides are very high or LDL-C is directly measured by a different method. Elevated remnant cholesterol connects the metabolic pattern to arterial inflammation and plaque risk. ApoB then shows how many atherogenic particles are carrying that cholesterol.
HDL-C and ApoA-I are context markers, not stand-alone treatment targets
HDL-C falls when HDL becomes triglyceride-rich and is cleared faster. ApoA-I gives additional information about the main HDL structural protein, but neither measurement fully captures HDL function. A low HDL-C result should therefore direct attention toward triglycerides, smoking, activity, insulin resistance, liver fat and inflammation. A high HDL-C result does not neutralise high ApoB, high Lp(a), hypertension, diabetes or existing plaque.
Lp(a) adds inherited risk
Lp(a) is an LDL-like ApoB particle with an additional apolipoprotein(a) attached. Its level is largely genetic and usually changes little with lifestyle. It should generally be measured at least once in adulthood. Because Lp(a) contributes cholesterol to LDL-C and adds thrombosis and inflammation-related risk, a person with high Lp(a) may need tighter control of all modifiable risk factors even when the rest of the metabolic terrain looks favourable. Statins do not meaningfully lower Lp(a) and can leave it unchanged or slightly higher, although they still reduce risk by lowering other ApoB particles.
6. The metabolic and organ biomarkers that explain the terrain
Glucose and insulin markers
Fasting glucose shows blood sugar at one moment. HbA1c estimates average glycaemic exposure over roughly two to three months, although anaemia, altered red-cell lifespan and kidney disease can distort it. Fasting insulin can reveal compensation before glucose rises, while HOMA-IR combines fasting glucose and insulin as a rough estimate of insulin resistance. A glucose tolerance test with insulin measurements can show delayed glucose disposal and excessive insulin output that fasting tests miss. Rising triglycerides, falling HDL-C, increasing waist size and high blood pressure often appear before diabetes is diagnosed.
Liver markers
ALT and AST indicate liver-cell stress, while GGT can reflect liver and bile-system strain and often tracks alcohol exposure or fatty liver. However, fatty liver can exist with normal enzymes. Ultrasound, controlled attenuation imaging or MRI-based methods assess liver fat more directly. When triglycerides are high, ALT or GGT is rising, waist size is increasing and insulin is elevated, the liver should be considered an active source of the lipid pattern rather than a passive observer.
Kidney and protein-loss markers
Creatinine and eGFR estimate filtration. Urine albumin-to-creatinine ratio detects early kidney vascular damage, while larger urine protein losses and low serum albumin raise concern for nephrotic physiology. Kidney disease also increases cardiovascular risk independently, so a lipid result that might be moderate in isolation can carry more significance when eGFR is reduced or albuminuria is present.
Thyroid markers
TSH is the pituitary signal asking the thyroid for more hormone, while free T4 is the available circulating thyroid hormone. High TSH with low free T4 supports overt hypothyroidism and can explain slower LDL clearance. Mild TSH elevation requires context, repeat testing and clinical judgement. Thyroid status should be stable before concluding that a persistent LDL rise is purely dietary or genetic.
Inflammation and vascular context
High-sensitivity C-reactive protein, or hsCRP, measures a liver response to inflammation. It does not identify the cause. Infection, injury, autoimmune activity, visceral fat, smoking and poor oral health can all raise it. Ferritin can also rise with inflammation or fatty liver, so it is not an iron-status marker in isolation. Blood pressure, smoking exposure, sleep apnoea, exercise capacity, family history, kidney disease and measures of existing plaque determine how aggressively ApoB exposure should be reduced.
Body composition and fuel overflow
Waist circumference and waist-to-height ratio often reveal visceral fat better than body weight alone. Blood pressure, resting heart rate, sleep quality and physical activity show how the wider system is coping. A normal body mass index does not exclude visceral fat, fatty liver or insulin resistance, particularly in people of South Asian ancestry. Therefore, the absence of obesity should never be used to dismiss a high-triglyceride, low-HDL pattern.
7. What statins do, step by step
Statins inhibit HMG-CoA reductase, a key enzyme in the liver’s cholesterol-making pathway. First, liver-cell cholesterol falls. Next, the liver activates a cholesterol-sensing programme called SREBP2. This programme increases LDL receptor production. More receptors are then placed on the liver surface, and more LDL, IDL and remnant particles are removed from blood. Consequently, LDL-C, non-HDL-C and ApoB fall.
The same sensing programme also increases PCSK9, which destroys LDL receptors. This response limits part of the statin effect, but the net result remains substantially more receptor-mediated clearance. It also explains why blocking PCSK9 can add a large LDL reduction when statin treatment alone is insufficient.
Statins primarily reduce LDL particle exposure. They also reduce VLDL remnants and triglycerides to a variable, usually modest degree, especially when baseline triglycerides are high. HDL-C may rise slightly, but this is not the main therapeutic mechanism. The clinically important change is lower circulating ApoB particle burden and lower cumulative entry of these particles into the artery wall.
Within plaque, lower ApoB exposure reduces further lipid delivery. Statin therapy also commonly lowers hsCRP and supports plaque stabilisation, which means making plaque less likely to rupture and form a clot. Large randomised trials show that lowering LDL with statins reduces heart attacks, strokes and other major vascular events. Accordingly, current guidelines retain statins as the foundation of pharmacological lipid lowering, especially in established cardiovascular disease and high-risk states.
8. What statins change in the terrain, and what they do not change
A statin changes one critical part of the terrain: it reduces the concentration and circulation time of ApoB-containing particles. This lowers the material available to enter and remain in artery walls. In a person with previous heart attack, stroke, stent, peripheral artery disease or other established atherosclerotic disease, this downstream protection is highly relevant even when lifestyle and metabolic health improve.
However, a statin does not automatically stop excess free-fatty-acid release from visceral fat. It does not directly restore muscle insulin sensitivity, remove liver fat, correct sleep apnoea, normalise thyroid hormone, stop kidney protein loss, reduce alcohol exposure, lower blood pressure, stop smoking or rebuild muscle. Therefore, triglycerides may remain high, HDL-C may remain low, glucose may continue to rise and fatty liver may persist even while LDL-C falls sharply.
This creates a common false reassurance. A good LDL-C response can mean that particle clearance has improved, yet it does not prove that the upstream metabolic system is healthy. Conversely, failure to correct the terrain does not make the LDL reduction unimportant. Both layers matter. Medication changes particle traffic; functional work changes the reasons that traffic became abnormal.
Statins can cause a small, dose-related rise in glucose and HbA1c and a modest increase in new diabetes diagnoses, mainly in people already close to the diabetes threshold. This does not mean statins create diabetes from nothing, nor does it usually outweigh cardiovascular benefit when treatment is clearly indicated. It means that fasting glucose, HbA1c, waist, activity, diet quality and muscle mass should be actively managed rather than ignored after prescribing.
Liver enzymes can rise mildly, while serious liver injury is rare. Muscle symptoms require a careful timeline and evaluation because exercise, thyroid disease, vitamin deficiencies, drug interactions and nocebo effects can produce similar symptoms. Creatine kinase is most useful when significant muscle pain, weakness or dark urine raises concern for true muscle injury. Medication decisions should be made with the prescribing clinician, especially after cardiovascular disease.
9. How to interpret common before-and-after patterns
When LDL-C, non-HDL-C and ApoB all fall substantially after a statin, the number and cholesterol load of atherogenic particles have both improved. If triglycerides also fall and HDL-C rises slightly, reduced VLDL-remnant traffic may be contributing. However, glucose, insulin, waist, liver fat, blood pressure and inflammation still determine whether the terrain improved.
When LDL-C falls more than ApoB, many cholesterol-poor particles may remain. This is common when triglycerides are high, diabetes is present or metabolic syndrome persists. Non-HDL-C and ApoB then reveal residual particle burden more clearly than LDL-C alone. The response should prompt attention to triglyceride production and clearance, not simply a higher statin dose without metabolic review.
When triglycerides stay high and HDL-C stays low despite a strong LDL response, the statin is doing its principal job, but the insulin-resistant liver-fat axis is still active. The next question is why: visceral fat, refined carbohydrate, alcohol, diabetes, low activity, sleep apnoea, thyroid dysfunction, kidney disease, medication or genetics. The answer comes from the biomarker network and the timeline, not from guessing.
When LDL-C is high but triglycerides are low and HDL-C is high, the pattern is not automatically benign and is not automatically insulin resistance. ApoB, non-HDL-C, Lp(a), thyroid function, diet composition, family history and plaque burden become decisive. High HDL-C does not cancel high ApoB, while low triglycerides do not prove that LDL particles cannot enter artery walls.
When all three values worsen suddenly, first check the conditions around testing. A recent high-carbohydrate or alcohol intake, non-fasting sample, acute illness, poorly controlled glucose, medication change, reduced thyroid function, rapid weight gain or kidney protein loss can shift results. Repeating the test under stable, comparable conditions can separate a persistent biological change from short-term noise.
10. The functional coaching framework
Functional interpretation begins with sequence. First, confirm that the result is real by checking fasting status, alcohol, illness, exercise, weight change, medication, laboratory method and the previous trend. Second, identify the dominant pattern: insulin-resistant high-triglyceride and low-HDL physiology, isolated clearance failure with high LDL, inherited Lp(a), kidney-related dyslipidaemia, thyroid-related dyslipidaemia or a mixed pattern. Third, quantify artery-entering particle burden using ApoB and non-HDL-C rather than relying on LDL-C alone.
Next, connect the pattern to the organs that control it. The fat tissue controls fatty-acid release. Muscle controls much of glucose disposal and fuel demand. The liver controls VLDL production, cholesterol synthesis and particle clearance. The thyroid sets metabolic pace and receptor activity. The kidneys influence triglyceride clearance and can drive major lipid production when protein is lost. The gut influences meal-derived particles, bile-acid recycling, fibre fermentation and total energy entry. Sleep, stress physiology and medication alter all of these systems through appetite, insulin sensitivity, hormone signalling and behaviour.
Then, define measurable levers. Food quality and amount should reduce energy overflow while preserving protein, micronutrients and muscle. Refined carbohydrate and excess alcohol are especially relevant when triglycerides are high. Saturated-fat exposure deserves review when LDL-C and ApoB rise, particularly on a low-carbohydrate diet. Soluble fibre, unsaturated fats, regular movement after meals, resistance training, aerobic work, sleep restoration and reduction of visceral fat can alter the upstream traffic. Thyroid, diabetes, kidney and liver disease require clinical treatment rather than lifestyle improvisation.
Finally, measure the response. A useful reassessment does not ask only whether LDL-C changed. It asks whether ApoB and non-HDL-C fell, whether triglycerides and remnant burden improved, whether HDL-C changed as expected, whether fasting insulin and glucose moved in the right direction, whether liver and kidney markers improved, whether blood pressure and waist changed, and whether the intervention is sustainable. This is how a person moves from chasing isolated numbers to controlling a biological system.
Coaching Message
Rising LDL-C, falling HDL-C and rising triglycerides often begin with one connected metabolic disturbance: excess fuel reaches the liver, VLDL production rises, clearance slows, HDL is stripped and cleared, and LDL is remodelled. However, LDL can also rise through receptor failure, thyroid dysfunction, genetic factors, kidney protein loss, bile-flow disease, hormones, medication or individual dietary response. Therefore, the correct interpretation depends on ApoB particle number, non-HDL-C, triglyceride-rich remnants, Lp(a), glucose-insulin control and organ function.
Statins do not merely hide cholesterol. They reduce liver cholesterol synthesis, increase LDL receptor activity and lower circulating ApoB particle exposure. That action reduces cardiovascular events and is especially important when atherosclerotic disease already exists. Yet statins do not automatically repair the metabolic terrain that produced high triglycerides, low HDL-C, fatty liver, high insulin or high blood pressure. The intelligent strategy is neither medication alone nor lifestyle alone. It is risk-led particle reduction combined with systems-led correction of the upstream biology.
Clinical note: This paper is educational and does not diagnose disease or recommend starting, stopping or changing medication. Lipid-lowering treatment and investigation of secondary causes should be personalised with the treating clinician, particularly after a cardiovascular event or when triglycerides are very high.
References
1. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Journal of the American College of Cardiology. Published online March 13, 2026. doi:10.1016/j.jacc.2025.11.016.
2. Ginsberg HN. Regulation of plasma triglycerides in insulin resistance and diabetes. Archives of Medical Research. 2005;36:232-240.
3. Choi SH, Ginsberg HN. Increased very-low-density lipoprotein secretion, hepatic steatosis, and insulin resistance. Trends in Endocrinology and Metabolism. 2011;22:353-363.
4. Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology. 2008;134:424-431.
5. Rashid S, Watanabe T, Sakaue T, Lewis GF. Mechanisms of HDL lowering in insulin-resistant, hypertriglyceridaemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clinical Biochemistry. 2003;36:421-429.
6. Wilkins JT, Li RC, Sniderman A, Chan C, Lloyd-Jones DM. Discordance between apolipoprotein B and LDL cholesterol in young adults predicts coronary artery calcification: the CARDIA study. Journal of the American College of Cardiology. 2016;67:193-201.
7. Varbo A, Benn M, Tybjærg-Hansen A, Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischaemic heart disease. Journal of the American College of Cardiology. 2013;61:427-436.
About Mathew Gomes
Functional Health, Nutrition & Longevity Coach
Throughout my career, I learned that valuable assets are not managed simply to prevent bankruptcy. They are protected—but they are also expected to grow. Yet I treated my most valuable asset, my health, very differently.
In my late fifties, a heart attack and two stents forced me to confront that mistake. Medical care saved my life, and medication gave me a vital insurance margin against another health bankruptcy. But I realised that insurance protects the downside; it does not grow the asset. That realisation led me to train in functional health and nutrition and combine it with my experience in executive coaching. I developed a structured process that connects symptoms, test trends, medication, nutrition, sleep, stress, movement and recovery—then turns that complexity into the right priorities and a measurable plan.
Today, I guide busy professionals whose medical numbers may be controlled, but who can feel their health becoming more fragile beneath the surface. Working alongside their doctors, we find what is driving the decline, rebuild function and create a better return from the actions they take every day.
Because the goal is to grow your health asset—so you extend the best years of the life you actually want to live, with energy, strength, clear thinking, independence and confidence in your body.
I am a certified Functional Health and Nutrition Practitioner (American Academy of Functional Health) and an accredited Executive Coach (ICF, EMCC).
Disclaimer
This white paper is provided for educational and informational purposes only. It is not intended to diagnose, treat, cure, prevent, or provide medical advice for any disease or health condition.
The author is a Functional Health, Nutrition and Longevity Coach, not a medical doctor. The content presented reflects a functional, educational perspective on health, lifestyle, nutrition, and risk factors, and is designed to support informed self-care and productive conversations with qualified healthcare professionals. Nothing in this document should be interpreted as a substitute for medical advice, diagnosis, or treatment from a licensed physician or other qualified healthcare provider. Readers should not start, stop, or change any medication, supplement, or medical treatment without consulting their prescribing clinician.
Individual responses to nutrition, lifestyle, supplements, and coaching strategies vary. Any actions taken based on this information are done at the reader’s own discretion and responsibility. If you have a medical condition, are taking prescription medication, or have concerns about your health, you are advised to seek guidance from a licensed healthcare professional before making changes.